In the hypertensive heart, epicardial arteries are not enlarged, despite increased total coronary flow related to augmented cardiac workload, wall stress, and left ventricular (LV) mass. The aims of this study were to assess the impact of different hemodynamic factors and LV mass on baseline left main coronary artery (LMA) size in hypertensive LV hypertrophy (LVH) and physiologic LVH, used as a pressure-independent model of hypertrophy.
I
n the hypertensive heart, epicardial coronary arteries are exposed to increased arterial pressure and increased coronary blood flow. Increased mechanical tension and stretching of arterial wall are believed to reduce arterial lumen, 1,2 whereas a prolonged increase in coronary flow is supposed to augment coronary artery luminal size. 3, 4 In systemic hypertension, an increase in global myocardial oxygen demand and total coronary blood flow primarily depends on an increase in cardiac workload, heart rate and peak systolic wall stress. 5, 6 A subsequent pressure-induced increase in LV wall thickness and development of LV hypertrophy (LVH) reduce the wall stress per cross-sectional area of myocardium and normalize myocardial energy demand per gram of myocardium. 6 -9 Specific coronary flow, ie, flow per gram of myocardium, returns to normal, 10 and total coronary flow to the hypertrophied ventricle should be influenced also by the magnitude of LV mass increment. 5 To understand better the impact of different hemodynamic and structural factors on epicardial vessel size in hypertensive and hypertrophied heart, the left main coronary artery (LMA) luminal size was measured, and its relationship to several possible determinants was tested, in hypertensive subjects without and with LVH as well as in normotensive subjects without clear-cut LVH and athletes with physiologic, pressure-independent model of LVH. LMA size was measured by means of transesophageal echocardiography as this noninvasive approach allows investigating healthy normotensive and asymptomatic hypertensive subjects.
Methods

Study Population
In a retrospective cohort of 141 normotensive and hypertensive subjects without significant coronary artery disease who underwent transesophageal echocardiography for the assessment of coronary vasodilator capacity, we selected 104 subjects (74%) in whom the luminal diameter of LMA was possible to measure from transesophageal approach. Of these, 26 were healthy normotensive volunteers with normal LV mass and geometry (eight women); 15 highly trained endurance athletes (marathon runners and triathletes, all men) with physiologic LVH; and 63 untreated patients with systodiastolic hypertension (26 women). Hypertension was defined as office blood pressure (BP) Ն140/90 mm Hg (average of three measurements over the course of 1 month). Primary myocardial and heart valve disease, diabetes, and dyslipidemia were exclusion criteria. Significant coronary artery disease was excluded on the basis of clinical history, resting and exercise electrocardiograms (ECG), dobutamine-atropine echocardiography (negative for regional wall motion abnormalities in all subjects), and, when needed, coronary angiography. Indication for coronary angiography was issued in 32 of 63 hypertensive patients, because of exercise ECG positive for myocardial ischemia (16 subjects), nonspecific ECG changes during exercise, with or without chest pain (10 subjects), and submaximal exercise test with a history of chest pain (six subjects). A total of 41 hypertensive subjects were newly diagnosed and previously untreated. A total of 22 subjects had been previously treated but did not achieve adequate BP control. Previous therapy had been stopped at least 2 weeks before the study for diagnostic work-up. The Institutional Review Committee approved the study, and all participants provided informed consent.
Study Protocol
All study subjects underwent standard transthoracic and transesophageal echocardiography. Transthoracic, two-dimensional targeted M-mode echocardiograms (SONOS 2500 and 5500, Philips Technologies, Andover, MA) were performed according to standard protocols, 11 and LV mass and mass index, relative wall thickness, peak systolic and endsystolic wall stress, and stress-adjusted midwall shortening (MWS) were calculated using standard formulas. [12] [13] [14] [15] Mean wall thickness was calculated as the average of septal and posterior wall end-diastolic thicknesses. LVH was defined as LV mass/height 2.7 Ͼ47 g/m 2,7 in women and Ͼ50 g/m 2,7 in men. 16 A relative wall thickness Ն0.45 was used as a cut-off value for concentric hypertrophy. LV volumes were determined using a Z-derived method, 17 and calculated stroke volume was used to estimate stroke work. 16 The BP used in stroke work and wall stress calculations was measured at the end of echocardiographic examination. Rate-pressure product was calculated as a product of heart rate and BP measured during LMA recording.
Transesophageal-Doppler echocardiography (SONOS 2500 and 5500, Philips Technologies, Andover, MA) was used to measure baseline luminal diameter of LMA as well as coronary flow velocity reserve (CFR) at the level of the left anterior descending artery. Shortly after the introduction of the probe to upper esophagus, proximal LMA was visualized and its "zoomed" images were acquired on an optical disc. Subsequently the proximal part of left anterior descending artery was detected and coronary flow velocity profile was recorded by Doppler technique at baseline, during adenosine infusion (700 g per kg of body weight over 5 min through an in-dwelling 18-G cannula in an antecubital vein) and for 5 min afterward as previously described. 18 The CFR was calculated as the ratio of coronary flow velocity during maximal response to adenosine and baseline coronary flow velocity.
Proximal luminal diameter was measured by bow compasses in digitized end-diastolic frames, in five different points, and the average was calculated. The mean of five averaged end-diastolic measurements derived from 5 different cardiac cycles was used for statistical analysis. The LMA cross-sectional area was calculated as: ⅐ luminal diameter 2 /4. The accuracy of transesophageal two-dimensional echocardiography for LMA diameter measurement was tested in 26 subjects in whom LMA diameter was measured by quantitative coronary angiography during diagnostic coronary angiography. The intra-and interobserver variability was evaluated in 15 subjects.
Statistical Analysis
Quantitative data are expressed as mean Ϯ SD. Analysis of variance was used to compare continuous variables. Analysis of covariance with separate slopes was used to compare regression coefficients; multiple comparisons were performed by the Turkey's test. The 2 test was used to compare categorical variables. Least-squares linear regression analysis was used to assess univariate relationships between continuous variables. Multiple regression analysis was used to study the independence of association of continuous variables that did not exhibit excessive collinearity with each other. Gender and smoking were treated as dummy variables. Statistical significance was set at a value of P Յ .05. Statistical analysis was performed with JMP software (SAS Institute, Cary, NC). The agreement between transesophageal echocardiography and quantitative coronary angiography for LMA diameter measurement was assessed according to the Bland-Altman approach.
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Results
Validation of TEE against quantitative coronary angiography for LMA diameter measurements showed adequate correlation (r ϭ 0.89, P Ͻ .0001), and a mean difference of Ϫ0.07 Ϯ 0.28mm (6.3 Ϯ 3.7%), with all points within Ϯ 2SD of the mean difference. The intra-and interobserver variability was 4.0 Ϯ 2.5 and 5.1 Ϯ 3.2%, respectively.
Characteristics of the Study Population
In the hypertensive group, 28 subjects had normal LV mass, and 35 had LVH. The LVH was classified as concentric and eccentric in 17 and 18 subjects, respectively. Age, anthropometric parameters and smoking habit were comparable between normotensive control subjects and hypertensive subgroups (Table 1) , whereas all athletes were nonsmokers. Comparing the two hypertensive subgroups, subjects with LVH had higher stroke volume and stroke work, as well as lower peak systolic wall stress, MWS, and CFR. Compared with sedentary control subjects, athletes with physiologic LVH had lower wall stress and MWS and higher CFR.
Baseline LMA luminal cross-sectional area of normotensive control subjects and hypertensive subjects with LVH was similar, whereas that of hypertensive subjects without LVH was lower. The LMA area of athletes with physiologic LVH was increased; however, when normalized for LV mass, LMA area per 100 g of LV mass was decreased not only in both hypertensive subgroups but also in athletes (Table 1) . Hypertensive subjects with concentric and eccentric LVH did not differ significantly for baseline LMA area (14.0 Ϯ 3.8 v 12.3 Ϯ 3.9 mm2; P ϭ .17) or LMA area per 100 g of LV mass (4.9 Ϯ 1.2 v 4.7 Ϯ 1.9 mm 2 /100 g; P ϭ .70).
LMA Size, Anthropometric Measures, and Possible Determinants of Myocardial Oxygen Demand
Relationships between LMA area and anthropometric parameters (body height, weight and surface area), BP components, hemodynamic determinants of myocardial oxygen demand (heart rate, rate-pressure product, and peak systolic wall stress), indices of chamber and myocardial performance (stroke volume, stroke work, MWS) and indices of LV structure (LV mass, mean wall thickness, relative wall thickness) were tested in univariate regression analyses. To assess whether any of the variables that correlated significantly with LMA size contributed independently to its variability, a multiple regression analysis was performed, entering LMA area as dependent variable and its correlates as independent variables.
In normotensive control subjects, LMA cross-sectional area increased with body height, weight, and surface area (r ϭ 0.39, 0.46 and 0.39; P Ͻ .05 for all), rate-pressure product (r ϭ 0.39, P Ͻ .05), stroke volume and stroke work (r ϭ 0.40 and 0.47; P Ͻ .05 for both) and with LV mass and mean wall thickness (r ϭ 0.67 and 0.62; P Ͻ .01 and 0.05) (Fig. 1) . In multiple regression analysis, including age, body surface area, rate-pressure product, stroke work and LV mass, only independent correlate of LMA size was LV mass (Table 2 ). When LV mass was replaced by mean wall thickness in a multiple model, wall thickness resulted as an independent correlate of LMA area (Table 2 ). In athletes with physiologic LVH, LMA area increased with CFR (r ϭ 0.65; P Ͻ .01), mean wall thickness (r ϭ 0.59; P Ͻ .05), and baseline heart rate (r ϭ 0.50; P ϭ .05) and showed a trend to increase with LV mass (r ϭ 0.45; P ϭ .09). In multiple regression analysis, CFR was the only independent correlate of LMA size (Table 2 ).
In the whole hypertensive population as well as in hypertensive subjects without LVH, LMA area increased with male sex (r ϭ 0.35 and 0.40; P Ͻ .01 and 0.05), body height (r ϭ 0.26 and 0.43; P Ͻ .05 for both), stroke volume (r ϭ 0.32 and 0.40; P Ͻ .05 for both), LV mass (r ϭ 0.40 and 0.44; P Ͻ .01 and 0.05), and mean wall thickness (r ϭ 0.31 and 0.27; P Ͻ .05 and N.S.), whereas it decreased with systolic BP (r ϭ Ϫ0.48 and -0.50; P Ͻ .01 for both) and pulse pressure (r ϭ Ϫ0.41 and -0.47; P Ͻ .01 for both) (Fig. 1) . In multiple regression model, including age, sex, body height, systolic BP, stroke volume and LV mass, independent correlates of LMA size were systolic BP and LV mass in the whole hypertensive population, and systolic BP in hypertensive subjects without LVH (Table 2) .
In hypertensive subjects with LVH, office systolic BP and pulse pressure were the only variables related to LMA area (r ϭ Ϫ0.51 and Ϫ0.35; P Ͻ .01 and 0.05). When divided according to LVH geometry, LMA size increased with LV mass in concentric (r ϭ 0.49, P Յ .05) but not in eccentric LVH. Inverse relationship between LMA area and systolic BP remained significant in both geometric patterns (r ϭ Ϫ0.50 and Ϫ0.59, P Յ .05 and .01).
Discussion
The results of the present study indicate that in both hypertensive and exercise-induced LVH, increase in LV mass is not associated with a proportional increase in baseline size of epicardial vessel. In the hypertensive heart, LMA luminal size is inversely related to office systolic BP, whereas in the athlete's heart LMA area seems to be mostly influenced by high-flow stimuli, as suggested by its relationship with CFR. Coronary vasculature of the hypertensive heart undergoes structural and functional changes related to changes in coronary flow and pressure. Physiologically, a chronic increase in total coronary flow, 4 related to a prolonged increase in global myocardial oxygen demand, should increase epicardial luminal diameter. In the hypertensive heart, global myocardial oxygen demand is increased according to specific interactions among augmented cardiac workload, wall stress, and myocardial mass. 6 -10 Previous studies, however, have demonstrated that despite an elevated myocardial oxygen demand and baseline coronary flow, luminal size of large coronary arteries is not increased in hypertensive patients. 20 -22 In the present study, LMA size at baseline increased with LV mass and wall thickness in the whole hypertensive population; however, hypertensive subjects with LVH had LMA area similar to that of normotensive control subjects, and, when normalized for LV mass magnitude, LMA size gradually decreased from normotensive control subjects through hypertensive subjects without to hypertensive subjects with LVH. These data indicate that in the hypertensive LVH, baseline epicardial vessel size does not increase in proportion to LV mass increment. Interestingly, within hypertensive subjects with LVH, LMA area was related to LV mass in concentric but not in eccentric LVH. Concentric LVH is supposed to normalize systolic wall stress and myocardial oxygen demand per gram of myocardium, 8, 9 and indeed, in this geometric pattern total coronary flow should be influenced by LV mass magnitude.
Inadequate increase in epicardial vessel size in the hypertensive LVH can be at least partially explained by our findings that in the whole hypertensive population as well as in subgroups with and without LVH or with concentric and eccentric LVH, LMA luminal size was inversely and independently related to office systolic BP. Several mechanisms might account for a negative influence of high BP on epicardial vessel size, including extracellular matrix remodeling and fibrosis, 1,2 increased coronary vasomotor tone, 23 and impaired endothelial function. 24 To evaluate the relationship between epicardial vessel size and determinants of myocardial oxygen demand and LV mass without confounding effect of high BP, normotensive subjects, both without and with LVH, were also studied. In normotensive control subjects, LMA size at baseline increased with body surface area, cardiac workload, and above all with LV mass and wall thickness, thus confirming previous angiographic findings suggesting that in normotensive heart total left ventricular mass is one of the determinants of coronary size. 25, 26 Athletes with physiologic LVH had significantly higher LMA size than control subjects without LVH, and furthermore LMA cross-sectional area increased with LV wall thickness. Yet, when normalized for LV mass magnitude, LMA area was lower in athletes with physiologic LVH than in control subjects without LVH, an observation suggesting that also in physiologic LVH an increase in baseline LMA size is not proportional to LV mass increment. The most important correlate of coronary size in an athlete's heart appears to be high-flow stimuli such as those occurring during maximal arteriolar dilation caused by high-dose adenosine or during a substantial increase in myocardial oxygen demand caused by high exercise load. 27 In addition, physiologic LVH was characterized by favorable changes at a microvascular level resulting in an increase in CFR, 27 ,28 a finding that is different from hypertensive LVH where CFR was significantly decreased.
This study had several limitations. First of all, it was performed on a retrospective cohort, and therefore the possible inter-relationships between BP reduction, LV mass regression, and changes in LMA size could not be evaluated. A noninvasive approach used for LMA size measurement allowed investigating healthy normotensive control subjects and athletes with physiologic LVH; however it had some restrictions. First, coronary size could be measured only at baseline and not at maximal dilation induced by nitrates, as systemic delivery of nitrates provokes significant hemody- namic changes and does not guarantee maximal vasodilating effect. Thus the effect of coronary vasomotor tone could not be eliminated, and structural changes of the epicardial vessel related to vascular remodeling could not be merely studied.
On the other hand, the measurement of coronary size at baseline provided an insight on coronary circulation under physiologic conditions. Second, by transesophageal echocardiography, coronary blood flow velocity can be measured in the left anterior descending artery whereas vessel diameter at the left main artery level. Consequently, this method does not allow calculation of volumetric flow, and the relationship between epicardial vessel size and blood flow could not directly be appraised. Third, the dominance of the coronary system could not be evaluated. However, angiographic findings in normal coronary arteries 29 demonstrated that the diameter of LMA is unaffected by anatomic distribution.
In conclusion, in the normotensive heart without clearcut LVH, baseline cross-sectional area of LMA increases with LV wall thickness and LV mass. In physiologic LVH, observed increase in epicardial vessel size is not proportional to LV mass increment but rather reflects the effect of frequent high flow stimuli caused by a substantial increase in myocardial oxygen demand during high exercise load. In the hypertensive LVH, LMA luminal area is comparable to that of normotensive control subjects without LVH and is inversely related systolic BP. An inadequate response of epicardial vessel size to hypertension-induced increase in coronary flow could lead to increase in flow velocity and shear stress, thus ultimately contributing to an accelerated development of coronary atherosclerosis. 30 
